FEC-PET/MRI demonstrated high sensitivity and diagnostic accuracy in the detection of clinical relevant primary prostate cancer lesions in a registered, prospective diagnostic trial design, thus presenting a reliable method for biopsy planning. Additionally, the imaging results supported the fitness of a Gleason score prediction. In furthering the progress of personalized medicine, our findings could serve to reduce the number of patients subjected to over-or undertreatment. Recently developed focal therapies with significantly lower rates of therapy-related adverse effects are dependent upon a precise imaging-guided therapeutic procedure to reduce the rates of post-therapeutic tumor relapse. Furthermore, 'active surveillance' strategies are still based on invasive techniques, and application of this new noninvasive diagnostic method promises to improve patient's compliance and outcome. To evaluate fully the potential of PET/MRI to assume a central position of PET/MRI in the therapeutic decision making process, a prospective, randomized, multi-arm design is mandatory for future clinical trials.
Introduction
Prostate cancer is second only to non-melanoma skin cancers as the most common cancer diagnosis affecting men in the Western world. It is, however, not the leading cause of cancer deaths, predominantly due to the fact that prostate cancer is a heterogeneous neoplasm concerning its aggressiveness, with peak diagnosis at the age of 69 years (1, 2) . Nevertheless, the slow-growing as well as the aggressive cases of this cancer (3) require tumor-and patientadapted treatment strategies. The current guidelines offer various treatment approaches based on risk stratifications that take into account patients' prostate specific antigen (PSA), the Gleason biopsy score and the diagnostic T-stage (4), all of which suffer from certain limitations; PSA values are apt to be affected by benign and inflammatory intraprostatic changes (5), Gleason scores depend on representative needle biopsy of the main tumor focus (6) , and T-staging with digital rectal examination (DRE) and transrectal ultrasonography (TRUS) lacks accuracy (7, 8) . These limitations imply considerable scope for improvement in the guiding of treatment.
The latest amended European guidelines recommend the use of endorectal magnetic resonance imaging (MRI) in cases where a non-organ-confined tumor stage is suspected and recommend the use of magnetic resonance spectroscopy (MRS), diffusion weighted images and dynamic contrast enhanced (DCE) sequences in ambiguous cases (9) . Although the tumor detection rate of T2 weighted images is limited, especially in the central and transitional zone and results of multiparametric MRI studies are promising but heterogeneous (10) (11) (12) (13) (14) (15) , MRI is widely accepted as the method of choice for the assessment of tumors at the organ margins (16) . Positron emission tomography (PET) with radioactive labeled choline has shown high sensitivity with respect to prostate cancer detection (17) but with the detriment of lower specificity due to unspecific uptake in benign and inflammatory intraprostatic lesions (18) . Author Manuscript Published OnlineFirst on April 24, 2014; DOI: 10.1158/1078-0432.CCR- tissue contrast on CT. The significance of these studies was further compromised by the fact that PET/CT lesions were compared with histology using sextant or segmental, rather than real lesion-based analysis. Studies with whole mount sections serving for histological validation are hitherto only available for [ 11 C]choline (21, 22) , which has slightly lower image resolution than [ 18 F]fluoroethylcholine (FEC) (23) , and is only available at sites with a cyclotron/radiochemistry facility due to the physical half-life of only 20 minutes for Carbon-
11.
To address these shortcomings, we conducted a single-center prospective clinical trial with FEC-PET/MRI in patients with suspected prostate cancer based on positive needle biopsy who were scheduled for radical prostatovesiculectomy. We hypothesized as primary objective that the combination of FEC-PET and endorectal MRI detects and locates the largest tumor lesion in the prostate with at least 90% sensitivity and, as a secondary objective, might contribute (e.g. by semiquantitative PET analysis) to the future treatment decisions of primary localised prostate cancer. Histologically reconstructed whole mount sections in a hundred-percent work-out of the prostate after radical prostatectomy served as the standard of reference.
Methods
The study was conducted according to Good Clinical Practice, the German pharmaceutical law (Arzneimittelgesetz) and radiation safety regulations (Strahlenschutzverordnung). We designed and carried out the study followed the principles embodied in the Declaration of Helsinki and the STARD criteria for diagnostic trials.
Patients' data was protected in accordance with the current German data-protection law Included for this study were patients with histologically diagnosed prostate carcinoma based on positive needle biopsy. Patients were > 50 years of age and were scheduled for radical prostatovesiculectomy the day after PET/MRI, which was conducted in a fasting condition for at least 12 hours, and at least three weeks following the biopsy. Exclusion criteria included all contraindications to MRI investigation, other known malignancies, surgical intervention less than 12 weeks before the PET/MRI examination, intake of cholinecontaining preparations, known severe liver parenchymal disorder, bronchial asthma, bradycardia, history of myocardial infarction and intolerance of Neurotropan®. Most of these exclusion criteria are conditions established by the Federal Institute for Drugs and Medical Devices intended to minimize potential or hypothetical adverse effects of FEC. Data were recorded using case report forms (CRF) for each involved discipline (nuclear medicine, radiology, urology and pathology) as well as standard operating procedures (SOP).
Magnetic Resonance Imaging
The MRI examination was performed using a 1.5-Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was accomplished with 5 mm T2w turbo spin echo (TSE) transverse and coronal short-tau inversion recovery (STIR) sequences. For prostate assessment, 3 mm endorectal T2w spin echo (SE) sagittal, transverse, and coronal sequences were acquired.
Transverse sequences were angled 90° to the intraprostatic bladder catheter to allow exact correlation with histological whole mount sections. A reference slice was defined in the central part of the organ, measured from the prostate base. This data guided the pathologist as a reference for the first cut of the resection preparation. Images were assessed by consensus of two experienced MRI-radiologists (WB, 12 years; BD, 16 years), who were blinded to the PET images and patient's urological data, but aware of the study inclusion criteria. MRI-only After MRI acquisition, the modular MRI table was released from the scanner, and lifted and fixed on the PET table system. The endorectal coil was not removed until the end of the PET investigation, so as to retain tissue positions for image fusion.
Positron Emission Tomography
PET scans were performed with an LSO full-ring scanner (ECAT ACCEL, Siemens, Erlangen) using a multiphase protocol starting with a "cold" transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames of one minute each, starting immediately upon administration of 3.3 MBq per kilogram body weight of FEC (Eckert & Ziegler EURO-PET Berlin GmbH, Berlin, Germany) as a bolus through a cubital vein. After a short gap necessitated by computer processing time, the whole body scan was performed starting at the upper thoracic aperture and proceeding down to the proximal femur. Acquisition parameters were 3 minutes per emission scan and 2 minutes per transmission scan for each of the five bed positions. As a result, the prostate region was re-scanned again at t1 = 48 (± 8) minutes after tracer injection. A delayed local acquisition of the lower pelvis at t2 = 71 (± 9) minutes of the lower pelvis with a six-minute emission and a two-minute transmission scan concluded the diagnostic acquisition procedure. Image reconstruction parameters consisted of two iterations and eight subsets for whole body and delayed scans and 
Statistical analysis
For the primary endpoint of this open, prospective, single-arm, single-treatment, single-center study, we predicted that the patient-based sensitivity in detecting the largest intraprostatic tumor lesion by PET/MRI should exceed 90%; the relationship between the number N of observed cases and the 95% confidence interval of a probability is given by N = 1.96
/ a 2 where p = 0.90 (the anticipated probability) and a = 0.095 (the desired diagnostic accuracy for determining the probability). To achieve a lower limit of the 95% confidence interval of at least 80%, this analysis predicts that the total of 38 patients as enrolled in the study would be sufficient. (for details see supplemental material).
Data are presented in summary and/or frequency tables. Summary tables present the number of observations as well as mean, standard deviation, minimum, median, and
Research. maximum, while frequency tables present absolute and relative frequencies. For determination of sensitivity, specificity, and diagnostic accuracy, '2x2' tables were used.
These were checked for independence using Fisher's exact test at a descriptive level. The respective 95% confidence intervals were calculated. For group statistics, in consideration that the observational units (lesions) are 'clustered' within patients, the confidence intervals were calculated for clustered samples, this being the most appropriate method for the present data set. Analyses were made according to the formula given in McCarthy and Guo (24) .
Receiver operating characteristic (ROC) analysis of SUVs and needle biopsies compared to Gleason scores was performed with the SAS PROC LOGISTIC's ROC routine (SAS Institute Inc., Cary, North Carolina, USA). The SUV cut-off was calculated by maximizing the Youden-Index and excluding any values where sensitivity or specificity equaled 100%.
Results
Thirty-eight patients meeting study criteria were enrolled. Patient and tumor characteristics are shown in Table 1 . The mean (±SD) interval between biopsy and PET/MRI was 65.3 ± 6.8 Table 4 ).
Discussion
In-vivo imaging techniques currently available for clinical use show certain limitations in the detection and characterization of primary prostate cancer lesions (10-13, 19, 25, 26).
Therefore, according to the current guidelines (9), the standardized diagnostic procedure for patients with suspected prostate cancer, is still based upon the serum PSA value, the DRE and TRUS, ultimately leading to sampling of the organ by a standardized needle biopsy (27). analyses. This is also supported by our finding that combined PET/MRI staging detected seminal vesicle invasion in five of seven and excessive extraprostatic extension in five of five patients, both of these observations are important parameters for individualized management when considering external radiation therapy or nerve sparing radical prostatectomy. These promising results have to be evaluated in a larger cohort of high risk patients.
A recent clinical study did not report any significant differences between the mortality of patients with clinically localized prostate cancer and a PSA value < 50ng/ml treated with 'radical prostatectomy' versus 'observation only' during a 10 years follow-up. However, radical prostatectomy was possibly associated with a decrease in all-cause mortality in intermediate-and high-risk tumors (35) . Furthermore, recently developed focal therapies with significantly lower rates of therapy-related adverse effects have come to depend on high spatial precision of imaging-guided therapy so as to reduce optimally the rates of posttherapeutic tumor relapse (36). Taking these facts into account and in support for the strategy of personalized medicine, the high sensitivity of non-invasive FEC-PET/MRI combined with the capacity for a precise lesion classification promises to reduce the number of patients subjected to over-or undertreatment and should also enhance the success rate of needle biopsies targeting the clinically significant tumor lesion.
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